01 6Gowling WLG (Canada) LLP
01 22491632
02 22614334
03 22615669
01 6Nilotinib hydrochloride monohydrate
01 6Capsule
01 22023-07-04
02 42026-07-18
Patent Expiration Date : 2023-07-04
Date Granted : 2009-11-10
Brand Name : TASIGNA
Patent Number : 2491632
Filing Date : 2003-07-04
Strength per Unit : 200 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2023-07-04
Date Granted : 2009-11-10
Patent Expiration Date : 2023-07-04
Date Granted : 2009-11-10
Brand Name : TASIGNA
Patent Number : 2491632
Filing Date : 2003-07-04
Strength per Unit : 150 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2023-07-04
Date Granted : 2009-11-10
Patent Expiration Date : 2026-07-18
Date Granted : 2013-11-12
Brand Name : TASIGNA
Patent Number : 2615669
Filing Date : 2006-07-18
Strength per Unit : 200 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2026-07-18
Date Granted : 2013-11-12
Patent Expiration Date : 2026-07-18
Date Granted : 2015-04-21
Brand Name : TASIGNA
Patent Number : 2614334
Filing Date : 2006-07-18
Strength per Unit : 200 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2026-07-18
Date Granted : 2015-04-21
Patent Expiration Date : 2026-07-18
Date Granted : 2013-11-12
Brand Name : TASIGNA
Patent Number : 2615669
Filing Date : 2006-07-18
Strength per Unit : 150 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2026-07-18
Date Granted : 2013-11-12
Patent Expiration Date : 2026-07-18
Date Granted : 2015-04-21
Brand Name : TASIGNA
Patent Number : 2614334
Filing Date : 2006-07-18
Strength per Unit : 150 mg
Dosage Form : Capsule
Human Or VET : Human
Route of Administration : Oral
Patent Expiration Date : 2026-07-18
Date Granted : 2015-04-21
